



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective July 1, 2023

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM[®]

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Actemra IV*	tocilizumab	Inflammatory Conditions	J3262	8/15/2022
Acthar gel	repository corticotropin	Miscellaneous Conditions	J0800	8/1/2022
Adakveo	crizanlizumab-tmca	Miscellaneous Conditions	J0791	1/1/2020
Aduhelm*	Aducanumab-avwa	Miscellaneous Conditions	J0172	7/1/2022
Aldurazyme	laronidase	Enzyme Deficiencies	J1931	7/21/2019
Amondys-45	casimersen	Muscular Dystrophies	J1426	5/1/2021
Amvuttra	vutrisiran	Amyloidosis	J0225	9/1/2022
Apretude	cabotegravir	HIV	J0739	3/1/2022
Aralast NP*	alpha1-proteinase inhibitor	Alpha 1 Deficiency	J0256	8/15/2022
Aranesp*	darbepoetin alfa	Blood Cell Deficiency	J0881	5/1/2019
Asceniv	immune globulin	Immune Deficiency	J1554	7/21/2019
Atgam	lymphocyte immune globulin	Immune Deficiency	J7504	3/1/2020
Aveed	testosterone undecanoate	Endocrine Disorders	J3145	5/1/2019
Avsola	infliximab-axxq	Inflammatory Conditions	Q5121	7/15/2020
Benlysta ^x	belimumab	Inflammatory Conditions	J0490	8/15/2022
Beovu	brolucizumab-dbli	Ophthalmic Conditions	J0179	11/11/2019
Berinert	c1 esterase inhibitor	Hereditary Angioedema	J0597	5/1/2019
Bivigam	immune globulin	Immune Deficiency	J1556	5/1/2019
Botox	onabotulinumtoxinA	Neuromuscular Conditions	J0585	5/1/2019
Brineura	cerliponase alfa	Enzyme Deficiencies	J0567	5/1/2019
Briumvi	ublituximab-xiiy	Multiple Sclerosis	C9399, J3590	3/1/2023
Byooviz	ranibizumab-nuna	Ophthalmic Conditions	Q5124	6/8/2022

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

● prior authorization applies to Medicare members only. Commercial, Healthcare Exchange and State of Wisconsin members require prior authorization through the pharmacy benefit.

× prior authorization applies to IV formulation for Medicare members only. Subcutaneous formulation requires prior authorization through pharmacy benefit for all lines of business.

± indicates the drug may be subject to site of care requirements

^ prior authorization applies to Medicare and State of Wisconsin members only. Coverage is a plan exclusion for all Healthcare Exchange and Commercial members.

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective July 1, 2023

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM[®]

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Cabenuva	cabotegravir/rilpivirine extended-release injection	HIV	J0741	5/1/2021
Cablivi	caplacizumab-yhdp	Blood Cell Deficiency	C9047	7/21/2019
Carimune NF	immune globulin	Immune Deficiency	J1566	5/1/2019
Cimzia*	certolizumab pegol	Inflammatory Conditions	J0717	8/15/2022
Cimerli	ranibizumab-eqrn	Ophthalmic Conditions	Q5128	8/10/2022
Cinqair	reslizumab	Asthma & Allergy	J2786	5/1/2019
Cinryze	c1 esterase inhibitor	Hereditary Angioedema	J0598	5/1/2019
Cortrophin gel	repository corticotropin	Miscellaneous Conditions	J0800	8/1/2022
Crysvita	burosumab-twza	Endocrine Disorders	J0584	10/1/2019
Cutaquig	immune globulin	Immune Deficiency	J1551, 90284	4/1/2022
Cuvitru	immune globulin	Immune Deficiency	J1555	4/1/2022
Cytogam	cytomegalovirus immune globulin	Immune Deficiency	J0850	3/1/2020
Depo-Testosterone	testosterone cypionate	Endocrine Disorders	J1071	2/1/2022
Durysta	bimatoprost	Ophthalmic Conditions	J7351	5/1/2020
Dysport	abobotulinumtoxinA	Neuromuscular Conditions	J0586	5/1/2019
Elaprase	idursulfase	Enzyme Deficiencies	J1743	7/21/2019
Enjaymo	sutimlimab – jome	Miscellaneous Conditions	J1302	4/1/2022
Entyvio	vedolizumab	Inflammatory Conditions	J3380	5/1/2019
Epogen*	epoetin alfa	Blood Cell Deficiency	J0885	5/1/2019
Epoprostenol	epoprostenol	Pulmonary Hypertension	J1325	5/1/2019
Evenity	romosozumab	Osteoporosis	J3111	10/1/2019
Evkeeza	evinacumab-dgnb	High Blood Cholesterol	J1305	5/1/2021

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

● prior authorization applies to Medicare members only. Commercial, Healthcare Exchange and State of Wisconsin members require prior authorization through the pharmacy benefit.

× prior authorization applies to IV formulation for Medicare members only. Subcutaneous formulation requires prior authorization through pharmacy benefit for all lines of business.

± indicates the drug may be subject to site of care requirements

^ prior authorization applies to Medicare and State of Wisconsin members only. Coverage is a plan exclusion for all Healthcare Exchange and Commercial members.

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective July 1, 2023

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM[®]

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Exondys 51	eteplirsen	Muscular Dystrophies	J1428	5/1/2019
Eylea	aflibercept	Ophthalmic Conditions	J0178	5/1/2019
Fabrazyme	agalsidase beta	Enzyme Deficiencies	J0180	7/21/2019
Fasenra*	benralizumab	Asthma & Allergy	J0517	8/15/2022
Fensolvi	leuprolide acetate	Endocrine Disorders	J1951	6/1/2020
Feraheme	ferumoxytol	Anemia	Q0138	3/1/2021
Flebogamma Dif	immune globulin	Immune Deficiency	J1572	5/1/2019
Flolan	epoprostenol	Pulmonary Hypertension	J1325	5/1/2019
Gamifant	emapalumab-lzsg	Miscellaneous Conditions	J9210	5/1/2019
Gammagard	immune globulin	Immune Deficiency	J1569	5/1/2019
Gammagard SD	immune globulin	Immune Deficiency	J1566	5/1/2019
Gammaked	immune globulin	Immune Deficiency	J1561	5/1/2019
Gammaplex	immune globulin	Immune Deficiency	J1557	5/1/2019
Gamunex-C	immune globulin	Immune Deficiency	J1561	5/1/2019
Givlaari	givosiran	Miscellaneous Conditions	J0223	1/1/2020
Glassia*	alpha1-proteinase inhibitor	Alpha 1 Deficiency	J0257	8/15/2022
Hemgenix^	etranacogene dezaparvovec-drlb	Hemophilia	J1411	3/1/2023
Hizentra	immune globulin	Immune Deficiency	J1559	4/1/2022
Hydroxyprogesterone Caproate	hydroxyprogesterone caproate	Hormonal Supplementation	J1729	11/11/2019
Hyqvia	immune globulin	Immune Deficiency	J1575	4/1/2022
Ilaris	canakinumab	Inflammatory Conditions	J0638	5/1/2019
Ilumya	tildrakizumab	Inflammatory Conditions	J3245	5/1/2020

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

● prior authorization applies to Medicare members only. Commercial, Healthcare Exchange and State of Wisconsin members require prior authorization through the pharmacy benefit.

× prior authorization applies to IV formulation for Medicare members only. Subcutaneous formulation requires prior authorization through pharmacy benefit for all lines of business.

± indicates the drug may be subject to site of care requirements

^ prior authorization applies to Medicare and State of Wisconsin members only. Coverage is a plan exclusion for all Healthcare Exchange and Commercial members.

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective July 1, 2023

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM[®]

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Inflectra	infliximab-dyyb	Inflammatory Conditions	Q5103	5/1/2019
Injectafer	ferric carboxymaltose	Anemia	J1439	3/1/2021
Kanuma	sebelipase alfa	Enzyme Deficiencies	J2840	7/21/2019
Krystexxa	pegloticase	Gout	J2507	5/1/2019
Lanreotide	lanreotide	Endocrine Disorders	J1932	3/9/2022
Lemtrada	alemtuzumab	Multiple Sclerosis	J0202	5/1/2019
Lamzedo	velmanase alfa-tycv	Enzyme Deficiencies	C9399, J3590	6/1/2023
Leqvio	inclisiran	High Blood Cholesterol	J1306	3/1/2022
Lucentis	ranibizumab	Ophthalmic Conditions	J2778	5/1/2019
Lumizyme	alglucosidase alfa	Enzyme Deficiencies	J0221	7/21/2019
Lupaneta Pack*	leuprolide acetate/norethindrone	Endocrine Disorders	J3490	5/1/2019
Lupron Depot*	leuprolide acetate	Endocrine Disorders	J9217	5/1/2019
Lupron Depot-Ped	leuprolide acetate	Endocrine Disorders	J1950	5/1/2019
Luxturna^	voretigene neparvovec-rzyl	Ophthalmic Conditions	J3398	5/1/2019
Macugen	pegaptanib sodium	Ophthalmic Conditions	J2503	5/1/2019
Makena	hydroxyprogesterone caproate	Hormonal Supplementation	J1726	5/1/2019
Mepsevii	vestronidase alfa-vjvk	Enzyme Deficiencies	J3397	7/21/2019
Mircera	methoxy peg-epoetin beta	Blood Cell Deficiency	J0888	5/1/2019
Monoferic	ferric derisomaltose	Anemia	J1437	3/1/2021
Myobloc	rimabotulinumtoxinB	Neuromuscular Conditions	J0587	5/1/2019
Naglazyme	galsulfase	Enzyme Deficiencies	J1458	7/21/2019
Neupogen*	filgrastim	Blood Cell Deficiency	J1442	5/1/2019

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

● prior authorization applies to Medicare members only. Commercial, Healthcare Exchange and State of Wisconsin members require prior authorization through the pharmacy benefit.

× prior authorization applies to IV formulation for Medicare members only. Subcutaneous formulation requires prior authorization through pharmacy benefit for all lines of business.

± indicates the drug may be subject to site of care requirements

^ prior authorization applies to Medicare and State of Wisconsin members only. Coverage is a plan exclusion for all Healthcare Exchange and Commercial members.

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective July 1, 2023

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM[®]

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Nexvazyme	avalglucosidase alfa-ngpt	Enzyme Deficiencies	J0219	10/1/2021
Nivestym*	filgrastim-aafi	Blood Cell Deficiency	Q5110	7/21/2019
Nplate	romiplostim	Blood Cell Deficiency	J2796	5/1/2019
Nucala*	mepolizumab	Asthma & Allergy	J2182	8/15/2022
Nulibry	fosdenopterin	Enzyme Deficiencies	C9399, J3590	6/1/2021
Nulojix	belatacept	Transplant	J0485	5/1/2019
Ocrevus±	ocrelizumab	Multiple Sclerosis	J2350	5/1/2019
Octagam	immune globulin	Immune Deficiency	J1568	5/1/2019
Onpattro	patisiran	Amyloidosis	J0222	10/1/2019
Orencia*	abatacept	Inflammatory Conditions	J0129	8/15/2022
Oxlumo	lumasiran	Metabolic Disorders	J0224	3/1/2021
Panzyga	immune globulin	Immune Deficiency	J1599	5/1/2019
Privigen	immune globulin	Immune Deficiency	J1459	5/1/2019
Procrit*	epoetin alfa	Blood Cell Deficiency	J0885	5/1/2019
Prolastin-C	alpha1-proteinase inhibitor	Alpha 1 Deficiency	J0256	5/1/2019
Radicava	edaravone	Muscular Dystrophies	J1301	5/1/2019
Reblozyl	luspatercept-aamt	Blood Cell Deficiency	J0896	1/1/2020
Remicade	infliximab	Inflammatory Conditions	J1745	5/1/2019
Remodulin	treprostinil	Pulmonary Hypertension	J3285	5/1/2019
Renflexis	infliximab-abda	Inflammatory Conditions	Q5104	5/1/2019
Retacrit*	epoetin alfa-epbx	Blood Cell Deficiency	Q5106	5/1/2019
Revcovi	elapegadomase-lvlr	Enzyme Deficiencies	J3590	5/1/2019

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

● prior authorization applies to Medicare members only. Commercial, Healthcare Exchange and State of Wisconsin members require prior authorization through the pharmacy benefit.

× prior authorization applies to IV formulation for Medicare members only. Subcutaneous formulation requires prior authorization through pharmacy benefit for all lines of business.

± indicates the drug may be subject to site of care requirements

^ prior authorization applies to Medicare and State of Wisconsin members only. Coverage is a plan exclusion for all Healthcare Exchange and Commercial members.

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective July 1, 2023

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Riabni*	rituximab-arrx	Inflammatory Conditions	Q5123	3/1/2021
Rituxan*	rituximab	Inflammatory Conditions	J9312	5/1/2019
Ruconest	c1 esterase inhibitor	Hereditary Angioedema	J0596	5/1/2019
Ruxience*	rituximab-pvvr	Inflammatory Conditions	Q5119	3/1/2020
Ryplazim	plasminogen, human-tvmh	Miscellaneous Conditions	J2998	3/1/2022
Sandostatin LAR*	Octreotide	Endocrine Disorders	J2353	1/1/2022
Saphnelo	anifrolumab	Inflammatory Conditions	J0491	10/1/2021
Scenesse	afamelanotide	Miscellaneous Conditions	J7352	1/1/2020
Signifor LAR	pasireotide pamoate	Endocrine Disorders	J2502	1/1/2022
Simponi Aria	golimumab	Inflammatory Conditions	J1602	5/1/2019
Skyrizi IV	risankizumab-rzaa	Inflammatory Conditions	J2327	9/1/2022
Skysona^	elivaldogene automovel	Neurologic Conditions	C9399	1/1/2023
Soliris	eculizumab	Blood Modifying Agents	J1300	5/1/2019
Somatuline Depot*	lanreotide	Endocrine Disorders	J1930	1/1/2022
Spevigo	spesolimab-sbzo	spesolimab-sbzo	J1747	11/1/2022
Spinraza	nusinersen	Muscular Dystrophies	J2326	5/1/2019
Spravato	esketamine	Miscellaneous Conditions	S0013	7/21/2019
Stelara IV	ustekinumab	Inflammatory Conditions	J3358	5/1/2019
Sunlenca	lenacapavir	HIV	C9399, J3590	3/1/2023
Supprelin LA*	Histrelin implant	Endocrine Disorders	J9226	5/1/2019
Syfovre	pegcetacoplan	Ophthalmic Conditions	C9399, J3590	6/1/2023
Synagis	palivizumab	Respiratory Syncytial Virus	90378	5/1/2019

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

• prior authorization applies to Medicare members only. Commercial, Healthcare Exchange and State of Wisconsin members require prior authorization through the pharmacy benefit.

× prior authorization applies to IV formulation for Medicare members only. Subcutaneous formulation requires prior authorization through pharmacy benefit for all lines of business.

± indicates the drug may be subject to site of care requirements

^ prior authorization applies to Medicare and State of Wisconsin members only. Coverage is a plan exclusion for all Healthcare Exchange and Commercial members.

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective July 1, 2023

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM[®]

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Tepezza	teprotumumab	Ophthalmic Conditions	J3241	3/1/2020
Testopel	testosterone implant	Endocrine Disorders	S0189	5/1/2019
Testosterone enanthate	testosterone enanthate	Endocrine Disorders	J3121	2/1/2022
Tezspire	tezepelumab-ekko	Asthma & Allergy	J2356	7/1/2023
Treprostinil	treprostinil	Pulmonary Hypertension	J3285	7/21/2019
Triptodur	triptorelin	Endocrine Disorders	J3316	5/1/2019
Trogarzo	Ibalizumab-uiy	HIV	J1746	9/1/2022
Truxima*	rituximab-abbs	Inflammatory Conditions	Q5115	7/21/2019
Tysabri	natalizumab	Multiple Sclerosis	J2323	5/1/2019
Tzield	teplizumab-mzwv	Diabetes	C9399, J3590	3/1/2023
Ultomiris	ravulizumab-cwvz	Blood Modifying Agents	J1303	5/1/2019
Uplizna	inebilizumab-cdon	Miscellaneous Conditions	J1823	7/15/2020
Vabysmo	faricimab-svoa	Ophthalmic Conditions	J2777	5/1/2022
Vantas*	Histrelin implant	Endocrine Disorders	J9225	5/1/2019
Veletri	epoprostenol	Pulmonary Hypertension	J1325	5/1/2019
Viltepso	viltolarsen	Muscular Dystrophies	J1427	11/15/2020
Vimizim	elosulfase alfa	Enzyme Deficiencies	J1322	7/21/2019
Vyepti	eptinezumab-jjmr	Miscellaneous Conditions	J3032	5/1/2020
Vyondys-53	golodisen	Muscular Dystrophies	J1429	3/1/2020
Vyvgart	efgartigimod alfa-fcab	Miscellaneous Conditions	J9332	3/1/2022
Xembify	immune globulin	Immune Deficiency	J1558	4/1/2022
Xenpozyme	olipudase alfa-rpcp	Enzyme Deficiencies	J0218	11/1/2022

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

● prior authorization applies to Medicare members only. Commercial, Healthcare Exchange and State of Wisconsin members require prior authorization through the pharmacy benefit.

× prior authorization applies to IV formulation for Medicare members only. Subcutaneous formulation requires prior authorization through pharmacy benefit for all lines of business.

± indicates the drug may be subject to site of care requirements

^ prior authorization applies to Medicare and State of Wisconsin members only. Coverage is a plan exclusion for all Healthcare Exchange and Commercial members.

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY PRIOR AUTHORIZATION DRUG LIST

Effective July 1, 2023

Register at <https://www.express-path.com>. If you have questions, please call (877) 787-8705.

CARECONTINUUM[®]

DRUG NAME	GENERIC DESCRIPTION	THERAPY CLASS	REIMBURSEMENT CODE	EFFECTIVE DATE
Xeomin	incobotulinumtoxinA	Neuromuscular Conditions	J0588	5/1/2019
Xiaflex	collagenase clostridium histolyticum	Miscellaneous Conditions	J0775	5/1/2019
Xolair*	omalizumab	Asthma & Allergy	J2357	8/15/2022
Xyosted	testosterone enanthate	Endocrine Disorders	J3490	2/1/2022
Zarxio*	filgrastim-sndz	Blood Cell Deficiency	Q5101	5/1/2019
Zemaira*	alpha1-proteinase inhibitor	Alpha 1 Deficiency	J0256	8/15/2022
Zoladex*	goserelin acetate implant	Endocrine Disorders	J9202	5/1/2019
Zolgensma^	onasemnogene abeparvovec-xioi	Muscular Dystrophies	J3399	6/1/2019
Zulresso	brexanolone	Miscellaneous Conditions	J1632	7/21/2019
Zynteglo^	betibeglogene autotemcel	Blood Cell Deficiency	C9399	1/1/2023

* denotes a drug that may be included in the eviCore Oncology Management Program. If the diagnosis is oncology, please contact eviCore at (855) 727-7444 or myportal@evicore.com

● prior authorization applies to Medicare members only. Commercial, Healthcare Exchange and State of Wisconsin members require prior authorization through the pharmacy benefit.

× prior authorization applies to IV formulation for Medicare members only. Subcutaneous formulation requires prior authorization through pharmacy benefit for all lines of business.

± indicates the drug may be subject to site of care requirements

^ prior authorization applies to Medicare and State of Wisconsin members only. Coverage is a plan exclusion for all Healthcare Exchange and Commercial members.

Please note that newly approved specialty drugs, not yet identified on this list, may be subject to prior authorization.